| Market Capitalization (Millions $) |
2,813 |
| Shares
Outstanding (Millions) |
53 |
| Employees |
182 |
| Revenues (TTM) (Millions $) |
285 |
| Net Income (TTM) (Millions $) |
96 |
| Cash Flow (TTM) (Millions $) |
52 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Soleno Therapeutics Inc. is a biopharmaceutical company based in Redwood City, California. The company specializes in the development and commercialization of therapeutic products for rare diseases. Soleno's main focus is on the treatment of rare genetic disorders known as Prader-Willi Syndrome (PWS) and Angelman Syndrome (AS).
PWS is a genetic disorder that affects appetite, growth, cognitive function, and behavior. Soleno's lead product candidate, Diazoxide Choline Controlled-Release (DCCR), is being developed as a potential treatment for abnormal hyperphagia (excessive hunger) and obesity associated with PWS. The company has conducted clinical trials to evaluate the safety and efficacy of DCCR, with promising results that indicate a potential therapeutic benefit for PWS patients.
In addition to PWS, Soleno Therapeutics is also developing therapy options for AS, a neurogenetic disorder characterized by severe developmental delays, movement disorders, and sleep disturbances. The company is exploring potential treatments to address the underlying genetic causes of AS and improve the quality of life for affected individuals.
Soleno Therapeutics has a dedicated team of scientists, researchers, and professionals committed to advancing novel therapies for rare diseases. The company aims to fill the unmet medical needs of patients and bring innovative treatments to the market.
Company Address: 100 Marine Parkway Redwood City 94065 CA
Company Phone Number: 213-8444 Stock Exchange / Ticker: NASDAQ SLNO
|
0.000%
